Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Phase 4 Completed 14 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess efficacy and safety of BeneFix® for prophylaxis in "Short-term" therapy and on demand therapy for all bleeding episodes of subjects with hemophilia B.

Timeline

Start: 2001-12
Primary completion: —
Completion: 2004-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BeneFIX	Protein / enzyme biologic	—	Intravenous

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Summary

Timeline

Drugs

Indications